癌症是死亡的主要原因，纤溶系统具有合作效应，促进肿瘤生长和转移的出现。本前瞻性研究旨在评估癌症患者的纤溶潜能，并使用荧光法同时测定凝血酶和纤溶酶生成来评估其与死亡结果的关联。本研究包括323名癌症患者和148名健康个体。在为期12个月的随访期间，68名患者死亡。与对照组相比，癌症患者的凝血酶生成存在变化，符合高凝血性特征，并且纤溶酶生成增加。死亡风险与两个凝血酶参数相关，无论是单变量分析还是多变量分析：峰值振幅（Wald 11.78，p < 0.001）和曲线下面积（Wald 8.0，p < 0.005），而纤溶酶则未观察到这样的关联。总之，这是第一项能够证明新诊断未治疗癌症患者同时评估凝血酶和纤溶酶生成的研究。癌症患者已被观察到表现出高凝血性特征。在本研究中，与凝血酶生成相关的两个参数，峰值振幅和曲线下面积，被确定并发现与死亡风险存在潜在关联。然而，未发现与纤溶酶生成相关的参数的关联。

Cancer is a leading cause of death, and the fibrinolytic system shows cooperative effects that facilitate the growth of tumors and the appearance of metastases. This prospective study aimed to evaluate the fibrinolytic potential in cancer patients and its association with mortality outcomes using the fluorometric method of simultaneous thrombin and plasmin generation. The study included 323 cancer patients and 148 healthy individuals. During the 12-month follow-up, 68 patients died. Compared to the control group, cancer patients showed alterations in thrombin production consistent with a hypercoagulability profile, and an increase in plasmin generation. Mortality risk was associated with two parameters of thrombin in both univariate and multivariable analysis: maximum amplitude (Wald 11.78, p < 0.001) and area under the curve (Wald 8.0, p < 0.005), while such associations were not observed for plasmin. In conclusion, this was the first study able to demonstrate the simultaneous evaluation of thrombin and plasmin generation in newly diagnosed untreated cancer patients. Patients with cancer have been observed to exhibit a hypercoagulable profile. During the study, two parameters linked to thrombin generation, MA and AUC, were identified and found to have a potential association with mortality risk. However, no associations were found with parameters related to plasmin generation.